Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: Effect on lipid profiles

Antiviral Therapy

Volumn 17, Issue 6, 2012, Pages 1011-1020

  Behrens, Georg ^a   Maserati, Renato ^b   Rieger, Armin ^c   Domingo, Pere ^d   Abel, Florian ^e   Wang, Hui ^f   Pearce, Gill ^g  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e Gilead Sciences GmbH   (Germany)

^f GILEAD SCIENCES   (United States)

^g Gilead Sciences Europe Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; CHOLESTEROL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BREAST FIBROADENOMA; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONJUNCTIVITIS; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GASTRITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY PAIN; LIPID ANALYSIS; MAINTENANCE CHEMOTHERAPY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RETROPERITONEAL SARCOMA; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT WITHDRAWAL;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL; DEOXYCYTIDINE; DIDEOXYNUCLEOSIDES; DRUG COMBINATIONS; DRUG SUBSTITUTION; FEMALE; HIV; HIV INFECTIONS; HUMANS; LAMIVUDINE; LIPIDS; LOPINAVIR; MALE; MEDICATION ADHERENCE; MIDDLE AGED; ORGANOPHOSPHORUS COMPOUNDS; RITONAVIR; TREATMENT OUTCOME;

EID: 84865719940     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2305     Document Type: Article

References (33)

1. Palella FJ, Delanay KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced HIV infection. N Engl J Med 1998; 338:853-860.
2. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV. Lancet 1998; 352:1725-1730.
3. Dubé MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidaemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003; 37:613-627.
4. Grover SA, Coupal L, Gilmore N, et al. Impact of dyslipidaemia associated with highly active antiretroviral therapy (HAART) on cardiovascular risk and life expectancy. Am J Cardiol 2005; 95:586-591.
5. European Guidelines for treatment of HIV infected adults in Europe, Version 6. (Updated October 2011. Accessed 31 May 2012.) Available from http://europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/ EACSGuidelines-v6.0-English.pdf
6. D:A:D Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
7. D:A:D Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723-1735.
8. D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371:1417-1426.
9. Cooper DA, Bloch M, Humphries A, et al. Simplification with fixed-dose tenofovir-emtricitabine or abacavir-lamivudine in adults with suppressed HIV replication (the steal study): a randomized, open-label, 96-week, non-inferiority trial. Conference on Retroviruses and Opportunistic Infections. 8-11 February 2009, Montreal, QC, Canada. Poster 576.
10. Behrens GM, Reiss P. Abacavir and cardiovascular risk. Curr Opin Infect Dis 2010; 23:9-14.
11. Lang S, Mary-Krause M, Cotte L, et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med 2010; 170:1228-1238.
12. Ribaudo HJ, Benson CA, Zheng Y, et al. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clin Infect Dis 2011; 52:929-940.
13. Fisher M, Moyle GJ, Shahmanesh M, et al. A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals. J Acquir Immune Defic Syndr 2009; 51:562-568.
14. Moyle GJ, Sabin CA, Cartledge J, et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006; 20:2043-2050.
15. Martínez E, Arranz JA, Podzamczer D, et al. A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression. J Acquir Immune Defic Syndr 2009; 51:290-297.
16. Martínez E, Larrousse M, Podzamczer D, et al. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction. AIDS 2010; 24:F1-F9.
17. Tungsiripat M, Kitch D, Glesby MJ, et al. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS 2010; 24:1781-1784.
18. Framingham Heart Study. Coronary heart disease (10-year risk). (Updated 23 April 2012. Accessed 5 May 2012.) Available from http://www. framinghamheartstudy.org/risk/coronary.html
19. Medical Dictionary for Regulatory Acitvities Version 12.0. (Updated 28 June 2012. Accessed 9 July 2012.) Available from http://www.meddramsso.com
20. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
21. Fisher M, Moyle GJ, Shahmanesh M, et al. A randomised comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals. J Acquir Immune Defic Syndr 2009; 51:562-568.
22. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. (Updated 3 November 2008. Accessed 25 January 2010.) Available from http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf
23. Valantin MA, Bittar R, de Truchis P, et al. Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients. J Antimicrob Chemother 2010; 65:556-561.
24. Lundgren JD, Battegay M, Behrens G, et al. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med 2008; 9:72-81.
25. Moyle GJ, Sabin CA, Cartledge J, et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006; 20:2043-2050.
26. Domingo P, Labarga P, Palacios R, et al. Improvement of dyslipidaemia in patients switching from stavudine to tenofovir: preliminary results. AIDS 2004; 18:1475-1478.
27. Llibre JM, Domingo P, Palacios R, et al. Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir. AIDS 2006; 20:1407-1414.
28. The Renal Association. The UK eCKD Guide. (Updated January 2009. Accessed 5 May 2012.) Available from http://www.renal.org/whatwedo/InformationResources/ CKDeGUIDE.aspx
29. Gallant JE, Parish MA, Keruly JC, et al. Changes in renal function associated with tenofovir disoproxil fumarate, compared with nucleoside reverse transcriptase inhibitor treatment. Clin Infect Dis 2005; 40:1194-1198.
30. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251-260.
31. DeJesus E, Ruane P, McDonals C, et al. Impact of switching virologically-suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine. HIV Clin Trials 2008; 9:103-114.
32. Cassetti I, Madruga JVR, Suleiman JMAH, et al. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral naive HIV-1 infected patients. HIV Clin Trials 2007; 8:164-172.
33. Mocroft A, Kirk O, Reiss P, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010; 24:1667-1678.